Tiotropium in COPD patients Source: Breathe 2008; 5: 271 Year: 2009
Tiotropium: COPD exacerbations and decline in FEV1 Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001
Salmeterol or ipratropium bromide/fenoterol in stable mild-to-moderate COPD Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Tiotropium reduces COPD exacerbations: the MISTRAL study Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004
Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Exacerbations of COPD Source: Eur Respir Rev, 27 (147) 170103; 10.1183/16000617.0103-2017 Year: 2018
Exacerbations of asthma and COPD Source: ERS Course 2018 - Summer school of adult respiratory medicine Year: 2018
Exacerbations of asthma and COPD Source: ERS Skills Course 2016 Year: 2016
Exacerbations of asthma and COPD Source: ERS Skills Course 2017 - Summer school of adult respiratory medicine Year: 2017
Exacerbations of COPD and treatment Source: International Congress 2018 – PG1 Asthma and chronic obstructive pulmonary disease Year: 2018
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Prevention of deteriorations in COPD on stepping up from tiotropium to umeclidinium/vilanterol Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Lung function indices for predicting mortality in COPD Source: Eur Respir J 2013; 42: 616-625 Year: 2013
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014
Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016